Search

JP-2026076271-A - Methods to reduce muscle atrophy and/or promote muscle regeneration

JP2026076271AJP 2026076271 AJP2026076271 AJP 2026076271AJP-2026076271-A

Abstract

[Problem] To provide a nutritional composition for use in a method to reduce muscle atrophy and/or promote muscle regeneration in subjects at risk of muscle atrophy. [Solution] The nutritional composition comprises (i) at least one of protein, fat, and carbohydrate, and (ii) an intact lipid membrane and exosomes isolated from milk having a natural miRNA agent retained within the exosome, and the method for promoting muscle regeneration comprises orally administering the nutritional composition. [Selection Diagram] Figure 1

Inventors

  • ロペス ペドロサ，ジョゼ マリア
  • ガルシア マルティネス，ジョージ

Assignees

  • アボット・ラボラトリーズ

Dates

Publication Date
20260511
Application Date
20260123
Priority Date
20200420

Claims (18)

  1. A method for reducing muscle atrophy and/or promoting muscle regeneration, comprising orally administering to a subject at risk of muscle atrophy a nutritional composition containing at least one of protein, fat, and carbohydrate, as well as bovine milk-isolated exosomes containing intact exosomes.
  2. A method according to claim 1, wherein more than 90% of the isolated bovine milk exosomes have a diameter of approximately 10 nanometers to approximately 250 nanometers.
  3. A method according to claim 1 or 2, wherein the nutritional composition contains about 0.001 to about 10 wt% of isolated bovine milk exosomes, based on the weight of the nutritional composition.
  4. A method according to any one of claims 1 to 3, wherein the subject is an adult over 40 years of age.
  5. A method according to any one of claims 1 to 4, wherein the subject is suffering from malnutrition, acquired immunodeficiency syndrome (AIDS), cancer, diabetes, chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), non-alcoholic fatty liver disease (NAFLD), or burns, or is receiving clinical treatment with corticosteroids.
  6. A method according to any one of claims 1 to 5, for reducing muscle atrophy.
  7. A method according to any one of claims 1 to 6, which promotes muscle regeneration.
  8. A method according to any one of claims 1 to 7, wherein the nutritional composition comprises protein.
  9. The method according to claim 8, wherein the nutritional composition further comprises fats and carbohydrates.
  10. A method according to any one of claims 1 to 9, wherein the nutritional composition comprises whole egg powder, egg yolk powder, egg white powder, whey protein, whey protein concentrate, whey protein isolate, whey protein hydrolysate, acid casein, casein protein isolate, sodium caseate, calcium caseate, potassium caseate, casein hydrolysate, milk protein concentrate, milk protein isolate, milk protein hydrolysate, skim milk powder, concentrated skim milk powder, whole bovine milk, partially or completely skimmed milk, coconut milk, soy protein concentrate, soy protein isolate, soy protein hydrolysate, and end A method comprising: green bean protein concentrate, pea protein isolate, pea protein hydrolysate, rice protein concentrate, rice protein isolate, rice protein hydrolysate, broad bean protein concentrate, broad bean protein isolate, broad bean protein hydrolysate, collagen protein, collagen protein isolate, meat protein, potato protein, chickpea protein, canola protein, mung bean protein, quinoa protein, amaranth protein, chia protein, hemp protein, flax protein, earthworm protein, insect protein, and at least one protein selected from combinations of two or more of these.
  11. A method according to any one of claims 1 to 10, wherein the nutritional composition comprises algal oil, canola oil, linseed oil, borage oil, safflower oil, high-oleic safflower oil, high-gamma-linolenic acid (GLA) safflower oil, corn oil, soybean oil, sunflower oil, high-oleic sunflower oil, cottonseed oil, coconut oil, fractionated coconut oil, medium-chain triglyceride (MCT) oil, palm oil, palm kernel oil, palm olein, long-chain polyunsaturated fatty acids, and at least one fat selected from two or more combinations thereof.
  12. A method according to any one of claims 1 to 11, wherein the nutritional composition comprises maltodextrin, hydrolyzed starch, modified starch, hydrolyzed corn starch, modified corn starch, polydextrose, dextrins, corn syrup, corn syrup solids, rice maltodextrin, soft powdery brown rice powder, brown rice syrup, sucrose, glucose, fructose, lactose, high-fructose corn syrup, honey, reduced maltose, erythritol, sorbitol, isomaltulose, sucromalt, pullulan, potato starch, corn starch, fructooligosaccharides, galactooligosaccharides, oat fiber, soy fiber A method comprising fiber, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, gellan gum, locust bean gum, konjac powder, hydroxypropyl methylcellulose, tragacanth gum, karaya gum, acacia gum, chitosan, arabinolactin, glucomannan, xanthan gum, alginic acid, pectin, low methoxypectin, high methoxypectin, cereal β-glucans, carrageenan, psyllium, fiber, fruit puree, vegetable puree, isomaltoligosaccharides, monosaccharides, disaccharides, tapioca-derived carbohydrates, inulin, and artificial sweeteners, as well as at least one carbohydrate selected from combinations of two or more of these.
  13. A method according to any one of claims 1 to 12, wherein the nutritional composition comprises, based on the weight of the nutritional composition, about 1 wt% to about 30 wt%, about 1 wt% to about 25 wt%, about 1 to about 20 wt%, about 1 to about 15 wt%, about 1 to about 10 wt%, or about 10 wt% to about 30 wt% of protein.
  14. A method according to any one of claims 1 to 13, wherein the nutritional composition contains, based on the weight of the nutritional composition, 0.5 wt% to 20 wt%, about 0.5 to about 15 wt%, about 0.5 to about 10 wt%, about 0.5 to about 5 wt%, or about 5 to about 15 wt% of fat.
  15. A method according to any one of claims 1 to 14, wherein the nutritional composition comprises, based on the weight of the nutritional composition, approximately 5 wt% to approximately 75 wt%, approximately 5 wt% to approximately 70 wt%, approximately 5 wt% to approximately 65 wt%, approximately 5 wt% to approximately 50 wt%, approximately 5 wt% to approximately 40 wt%, approximately 5 wt% to approximately 30 wt%, approximately 5 wt% to approximately 25 wt%, approximately 10 wt% to approximately 65 wt%, approximately 20 wt% to approximately 65 wt%, approximately 30 wt% to approximately 65 wt%, approximately 40 wt% to approximately 65 wt%, or approximately 15 wt% to approximately 25 wt% of carbohydrates.
  16. A method according to any one of claims 1 to 15, wherein the nutritional composition is a liquid nutritional composition, and the nutritional composition comprises, based on the weight of the nutritional composition, about 1 to about 15 wt% protein, about 0.5 to about 10 wt% fat, and about 5 to about 30 wt% carbohydrates.
  17. A method according to any one of claims 1 to 15, wherein the nutritional composition is a powdered nutritional composition, and the nutritional composition comprises, based on the weight of the nutritional composition, about 10 to about 30 wt% of protein, about 5 to about 15 wt% of fat, and about 30 wt% to about 65 wt% of carbohydrates.
  18. A method according to any one of claims 1 to 17, wherein the nutritional composition comprises at least one protein, including milk protein concentrate and/or soy protein isolate; at least one fat, including canola oil, corn oil, coconut oil and/or fish oil; and at least one carbohydrate, including maltodextrin, sucrose and/or short-chain fructooligosaccharides.

Description

This invention relates to a method for reducing muscle atrophy and/or promoting muscle regeneration by orally administering a nutritional composition containing bovine milk-isolated exosomes that include undamaged exosomes. Skeletal muscle is the most abundant tissue in the body. The volume and function of skeletal muscle are major determinants of muscle strength, endurance, and physical ability throughout life. Skeletal muscle is a plastic tissue that exhibits changes in muscle mass and muscle fiber size depending on physiological and pathological conditions. Skeletal muscle mass is maintained by a delicate balance between protein synthesis and protein breakdown. Muscle is a highly adaptable tissue that responds quickly to anabolic stimuli such as physical activity or food intake. Conversely, prolonged starvation or inactivity is known to cause rapid muscle weakness. Muscle atrophy occurs when the rate of protein breakdown exceeds the rate of protein synthesis. This phenomenon occurs under a variety of conditions. For example, muscle fatigue is a common feature associated with poor prognosis and negative outcomes in diseases such as acquired immunodeficiency syndrome (AIDS), cancer, diabetes, chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), non-alcoholic fatty liver disease (NAFLD), and burns. Catalytic states, in which muscle weakness prevails over muscle growth, also occur during human life. In adults, muscle mass typically begins to decline gradually from around 35 to 40 years of age, at a rate of 0.4 to 1.0% per year. This age-related decline in muscle mass and strength, which occurs in otherwise healthy aging individuals, is called sarcopenia (muscle weakness). This decline in muscle mass and strength can increase the risk of developing metabolic diseases and/or physical disabilities, and can lead to an inability to maintain daily function. There is a consensus in the scientific community that muscle atrophy is associated with a variety of undesirable outcomes, including delayed recovery from illness, reduced quality of life, physical disability, decreased resting metabolic rate, decreased insulin sensitivity, delayed wound healing, and increased healthcare costs. Skeletal muscle tissue responds to anabolic stimuli—that is, protein intake through diet and physical activity—for protein synthesis. However, for individuals under the influence of injury, illness, and/or aging, it is not always possible to perform physical activity sufficient for protein synthesis to maintain or increase muscle mass. Therefore, it is desirable to develop nutritional intervention strategies that resist or mitigate the decline in muscle mass and strength, and/or promote muscle regeneration. This invention relates to a method for reducing muscle atrophy and/or promoting muscle regeneration in subjects at risk of muscle atrophy. The object of this invention is to provide such a method, particularly suitable for subjects where it is not easy and/or possible to implement physical activity interventions for protein synthesis sufficient to maintain or increase muscle mass. In one embodiment, the present invention relates to a method for reducing muscle atrophy and/or promoting muscle regeneration in subjects at risk of muscle atrophy. This method involves orally administering a nutritional composition containing at least one of proteins, fats, and carbohydrates, as well as bovine milk-isolated exosomes containing intact exosomes. The present invention offers advantages in that it provides a simple method for reducing muscle atrophy and/or promoting muscle regeneration in subjects at risk of muscle atrophy. This method may be performed continuously for a period of time necessary, depending on the subject's risk of muscle atrophy. These and other advantages of the present invention will be further understood through the detailed description provided herein. Specific aspects of the present invention will be specifically illustrated with the following drawings. As described in Example 2, we have shown proteolysis with dexamethasone (C) and proteolysis in the presence of undamaged bovine milk isolated exosomes (Ex).As described in Example 2, this shows Akt phosphorylated (C) myotubes incubated alone and incubated with isolated bovine milk exosomes.As described in Example 2, the effects of various components on the transcriptional activity of the ubiquitin promoter are demonstrated.As described in Example 2, the effects of various components on the atrogin-1 protein level are shown.As described in Example 2, the effects of various components on FoxO transcription activity are demonstrated.As described in Example 2, the effects of undamaged bovine milk-isolated exosomes and sonication-treated exosomes on myoblast cells Mef2 are shown, respectively. While the general concept of the present invention can take many different embodiments, the specific embodiments described herein are those described in detai